Skip to main content
. 2014 Jun 7;14:105. doi: 10.1186/1471-230X-14-105

Figure 4.

Figure 4

Recurrence-free survival (RFS) in high-risk patients with imatinib adjuvant therapy. (A) RFS by mitosis count > 10/50 HPF in patients with imatinib adjuvant therapy. (B) RFS by serosal invasion in patients with imatinib adjuvant therapy.